A Phase 3 interventional study of Dapagliflozin and Saxagliptin in Diabetes Mellitus, Type 2, sponsored by AstraZeneca. Completed at 122 sites in 23 countries. Open to participants aged 10 Years to 18 Years. Per ClinicalTrials.gov, last updated 2024-06-21.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 — 15 open to participants now, 19 under way, 5 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 2.
Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, this one is the 49th largest by enrollment, is one of 13 that started in 2017, is one of 47 in phase 3, and was the 99th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →15 of the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, China and 10 more countries
Ages 18+
AstraZeneca · Sites in United States, Argentina, Brazil and 21 more countries
Ages 18+
Junjie Yang · Sites in China
Ages 18–78
Herlev and Gentofte Hospital · Sites in Denmark
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
By country, each count listing its studies:
dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 10 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
180 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 21 · Phase 3 53 · Phase 4 77
First in 2005; this study’s year is marked. 13 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 256 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 82 across the 180 interventional studies. Of the 136 that completed or were terminated, 68 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
82 of 180 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
345 studies in Diabetes Mellitus, Type 2 by AstraZeneca: 13 open now, 15 under way, 9 of them phase 3. Of 325 finished, 149 (46%) have results posted.
Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, this one is the 113th largest by enrollment of the 280 interventional ones that give a count, is one of 22 that started in 2017, is one of 119 in phase 3, and was the 285th registered.
AstraZeneca’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
6 of the studies testing dapagliflozin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07311551Bhavya Bhavya, MDA Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI) | 2026-12 |
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
| NCT07614230Junjie YangSGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes | 2027-06-01 |
| NCT07891234Sherihan AboElyazed Mohamed KhalilEffect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance | 2027-10-01 |
| NCT05938712University Health Network, TorontoThe Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients | 2027-10-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Among AstraZeneca’s 345 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to determine if there will be a greater mean reduction from baseline in glycated hemoglobin (HbA1c) achieved after 26 weeks of oral double-blind add-on therapy of dapagliflozin or saxagliptin compared to placebo in paediatric T2DM patients with HbA1c levels of 6.5 to 10.5% on diet and exercise and metformin, insulin, or metformin plus insulin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral route. Start with a low dose of dapagliflozin administered once daily and remain on the low dose regardless of your HbA1c at week 12.
Drug: Dapagliflozin
Oral route. Start with a low dose of Dapagliflozin administered once daily and up titrate to the high dose Dapagliflozin administered once daily if HbA1c \>= 7% at week 12
Drug: Dapagliflozin
Oral route. Start with a low dose of saxagliptin administered once daily and remain on the low dose regardless of your HbA1c at week 12
Drug: Saxagliptin
Oral route. Start with a low dose of saxagliptin administered once daily and up titrate to the high dose if HbA1c \>= 7% at week 12
Drug: Saxagliptin
Oral route. Placebo tablets administered for 52 weeks
Drug: Placebo
Tablets, Oral, 5mg , Once daily Tablets, Oral, 10mg, Once daily
Also known as: Forxiga
Tablets, Oral, 2.5mg Once daily Tablets, Oral, 5mg, Once daily
Also known as: Onglyza
Matching placebo to dapagliflozin 5mg and 10 mg/saxagliptin 2.5 mg and 5 mg, Tablets, oral, Once daily
Dapagliflozin Versus Placebo: Adjusted Mean Change From Baseline in HbA1c at Week 26
Data was analysed with an ANCOVA model with treatment, sex, age group and background antidiabetes medication as factors and Baseline HbA1c as covariate. Missing Week 26 data was handled based on multiple imputation washout (MI-WO) within each arm using the data from placebo participants with Week 26 data.
Time frame: Baseline and Week 26
Saxagliptin Versus Placebo: Adjusted Mean Change From Baseline in HbA1c at Week 26
Data was analysed with an ANCOVA model with treatment, sex, age group and background antidiabetes medication as factors and Baseline HbA1c as covariate. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data.
Time frame: Baseline and Week 26
Dapagliflozin Low-dose/High-dose Versus Placebo (Weighted): Adjusted Mean Change From Baseline in HbA1c at Week 26
Data was analysed with an ANCOVA model with treatment, sex, age group and background antidiabetes medication as factors and Baseline HbA1c as covariate. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data. Dapagliflozin participants were weighted as follows: participants who had HbA1c \< 7% at Week 12 and remained on low-dose were assigned a weight of 1; participants who had HbA1c \>= 7% at Week 12 and continued on the low-dose were assigned a weight of 0; participants who had HbA1c \>= 7% at Week 12 and received the high-dose were assigned a weight of 2; all participants who do not undergo second randomisation were assigned a weight of 1. Placebo participants were assigned a weight of 1.
Time frame: Baseline and Week 26
Saxagliptin Low-dose/High-dose Versus Placebo (Weighted): Adjusted Mean Change From Baseline in HbA1c at Week 26
Data was analysed with an ANCOVA model with treatment, sex, age group and background antidiabetes medication as factors and Baseline HbA1c as covariate. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data. Saxagliptin participants were weighted as follows: participants who had HbA1c \< 7% at Week 12 and remained on low-dose were assigned a weight of 1; participants who had HbA1c \>= 7% at Week 12 and continued on the low-dose were assigned a weight of 0; participants who had HbA1c \>= 7% at Week 12 and received the high-dose were assigned a weight of 2; all participants who do not undergo second randomisation were assigned a weight of 1. Placebo participants were assigned a weight of 1.
Time frame: Baseline and Week 26
Dapagliflozin Low-dose Versus Placebo (Weighted): Adjusted Mean Change From Baseline in HbA1c at Week 26
Data was analysed with an ANCOVA model with treatment, sex, age group and background antidiabetes medication as factors and Baseline HbA1c as covariate. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data. Dapagliflozin participants were weighted as follows: participants who had HbA1c \< 7% at Week 12 and remained on low-dose were assigned a weight of 1; participants who had HbA1c \>= 7% at Week 12 and continued on the low-dose were assigned a weight of 2; participants who had HbA1c \>= 7% at Week 12 and received the high-dose were assigned a weight of 0; all participants who do not undergo second randomisation were assigned a weight of 1. Placebo participants were assigned a weight of 1.
Time frame: Baseline and Week 26
Saxagliptin Low-dose Versus Placebo (Weighted): Adjusted Mean Change From Baseline in HbA1c at Week 26
Data was analysed with an ANCOVA model with treatment, sex, age group and background antidiabetes medication as factors and Baseline HbA1c as covariate. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data. Saxagliptin participants were weighted as follows: participants who had HbA1c \< 7% at Week 12 and remained on low-dose were assigned a weight of 1; participants who had HbA1c \>= 7% at Week 12 and continued on the low-dose were assigned a weight of 2; participants who had HbA1c \>= 7% at Week 12 and received the high-dose were assigned a weight of 0; all participants who do not undergo second randomisation were assigned a weight of 1. Placebo participants were assigned a weight of 1.
Time frame: Baseline and Week 26
Dapagliflozin Versus Placebo: Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26
Data was analysed with an ANCOVA model with treatment, sex, age group and background antidiabetes medication as factors and Baseline FPG as covariate. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data.
Time frame: Baseline and Week 26
Saxagliptin Versus Placebo: Adjusted Mean Change From Baseline in FPG at Week 26
Data was analysed with an ANCOVA model with treatment, sex, age group and background antidiabetes medication as factors and Baseline FPG as covariate. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data.
Time frame: Baseline and Week 26
Dapagliflozin Low-dose/High-dose Versus Placebo (Weighted): Adjusted Mean Change From Baseline in FPG at Week 26
Data was analysed with an ANCOVA model with treatment, sex, age group and background antidiabetes medication as factors and Baseline FPG as covariate. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data. Dapagliflozin participants were weighted as follows: participants who had HbA1c \< 7% at Week 12 and remained on low-dose were assigned a weight of 1; participants who had HbA1c \>= 7% at Week 12 and continued on the low-dose were assigned a weight of 0; participants who had HbA1c \>= 7% at Week 12 and received the high-dose were assigned a weight of 2; all participants who do not undergo second randomisation were assigned a weight of 1. Placebo participants were assigned a weight of 1.
Time frame: Baseline and Week 26
Saxagliptin Low-dose/High-dose Versus Placebo (Weighted): Adjusted Mean Change From Baseline in FPG at Week 26
Data was analysed with an ANCOVA model with treatment, sex, age group and background antidiabetes medication as factors and Baseline FPG as covariate. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data. Saxagliptin participants were weighted as follows: participants who had HbA1c \< 7% at Week 12 and remained on low-dose were assigned a weight of 1; participants who had HbA1c \>= 7% at Week 12 and continued on the low-dose were assigned a weight of 0; participants who had HbA1c \>= 7% at Week 12 and received the high-dose were assigned a weight of 2; all participants who do not undergo second randomisation were assigned a weight of 1. Placebo participants were assigned a weight of 1.
Time frame: Baseline and Week 26
Dapagliflozin Low-dose Versus Placebo (Weighted): Adjusted Mean Change From Baseline in FPG at Week 26
Data was analysed with an ANCOVA model with treatment, sex, age group and background antidiabetes medication as factors and Baseline FPG as covariate. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data. Dapagliflozin participants were weighted as follows: participants who had HbA1c \< 7% at Week 12 and remained on low-dose were assigned a weight of 1; participants who had HbA1c \>= 7% at Week 12 and continued on the low-dose were assigned a weight of 2; participants who had HbA1c \>= 7% at Week 12 and received the high-dose were assigned a weight of 0; all participants who do not undergo second randomisation were assigned a weight of 1. Placebo participants were assigned a weight of 1.
Time frame: Baseline and Week 26
Saxagliptin Low-dose Versus Placebo (Weighted): Adjusted Mean Change From Baseline in FPG at Week 26
Data was analysed with an ANCOVA model with treatment, sex, age group and background antidiabetes medication as factors and Baseline FPG as covariate. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data. Saxagliptin participants were weighted as follows: participants who had HbA1c \< 7% at Week 12 and remained on low-dose were assigned a weight of 1; participants who had HbA1c \>= 7% at Week 12 and continued on the low-dose were assigned a weight of 2; participants who had HbA1c \>= 7% at Week 12 and received the high-dose were assigned a weight of 0; all participants who do not undergo second randomisation were assigned a weight of 1. Placebo participants were assigned a weight of 1.
Time frame: Baseline and Week 26
Percentage of Participants With Baseline HbA1c ≥ 7% Who Achieved HbA1c < 7% at Week 26
A logistic regression model adjusting for sex, age group, background antidiabetes medication and Baseline HbA1c was used. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data.
Time frame: Baseline and Week 26
Low-dose/High-dose Versus Placebo (Weighted): Percentage of Participants With Baseline HbA1c ≥ 7% Who Achieved HbA1c < 7% at Week 26
A weighted logistic regression model adjusting for sex, age group, background antidiabetes medication and Baseline HbA1c was used. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data. Participants were weighted as follows: participants who had HbA1c \< 7% at Week 12 and remained on low-dose were assigned a weight of 1; participants who had HbA1c \>= 7% at Week 12 and continued on the low-dose were assigned a weight of 0; participants who had HbA1c \>= 7% at Week 12 and received the high-dose were assigned a weight of 2; all participants who do not undergo second randomisation were assigned a weight of 1. Placebo participants were assigned a weight of 1.
Time frame: Baseline and Week 26
Low-dose Versus Placebo (Weighted): Percentage of Participants With Baseline HbA1c ≥ 7% Who Achieved HbA1c < 7% at Week 26
A weighted logistic regression model adjusting for sex, age group, background antidiabetes medication and Baseline HbA1c was used. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data. Participants were weighted as follows: participants who had HbA1c \< 7% at Week 12 and remained on low-dose were assigned a weight of 1; participants who had HbA1c \>= 7% at Week 12 and continued on the low-dose were assigned a weight of 2; participants who had HbA1c \>= 7% at Week 12 and received the high-dose were assigned a weight of 0; all participants who do not undergo second randomisation were assigned a weight of 1. Placebo participants were assigned a weight of 1.
Time frame: Baseline and Week 26
Low-dose Versus Uptitration to the High Dose: Adjusted Mean Change From Baseline in HbA1c at Week 26
Data was analysed with an ANCOVA model with treatment, sex, age group and background antidiabetes medication as factors and Baseline HbA1c as covariate. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data.
Time frame: Baseline and Week 26
Low-dose Versus Uptitration to the High Dose: Adjusted Mean Change From Baseline in FPG at Week 26
Data was analysed with an ANCOVA model with treatment, sex, age group and background antidiabetes medication as factors and Baseline FPG as covariate. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data.
Time frame: Baseline and Week 26
Dapagliflozin Low-dose Versus Uptitration to the High Dose: Percentage of Participants With Baseline HbA1c ≥ 7% Who Achieved HbA1c < 7% at Week 26
A Fisher's exact test was used and unadjusted difference in percentage of participants and Clopper-Pearson CIs presented using imputed data. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data.
Time frame: Baseline and Week 26
Saxagliptin Low-dose Versus Uptitration to the High Dose: Percentage of Participants With Baseline HbA1c ≥ 7% Who Achieved HbA1c < 7% at Week 26
A Fisher's exact test was used and unadjusted difference in percentage of participants and Clopper-Pearson CIs presented using imputed data. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data.
Time frame: Baseline and Week 26
A total of 245 patients were randomised from 94 sites in 21 countries. Participants were initially randomised in a 1:1:1 ratio to receive dapagliflozin 5 mg, saxagliptin 2.5 mg, or placebo.
| Milestone | Dapagliflozin | Saxagliptin | Placebo |
|---|---|---|---|
| Started | 81 | 88 | 76 |
| Week 14 no uptitration randomisation | 39 | 36 | 0 |
| Week 14 uptitration randomisation | 42 | 52 | 0 |
| Completed | 76 | 83 | 68 |
| Not completed | 5 | 5 | 8 |
| Withdrew: Withdrawal by subject | 2 | 4 | 6 |
| Withdrew: Withdrawal by parent/guardian | 1 | 1 | 1 |
| Withdrew: Lost to follow-up | 2 | 0 | 1 |
| Milestone | Dapagliflozin | Saxagliptin | Placebo |
|---|---|---|---|
| Started | 76 | 83 | 68 |
| Randomised withdrawal patients data set | 13 | 25 | 8 |
| Excluded from randomised withdrawal patients data set | 68 | 63 | 68 |
| Randomised to continue metformin | 6 | 12 | 2 |
| Randomised metformin withdrawal | 7 | 13 | 6 |
| Completed | 75 | 79 | 61 |
| Not completed | 1 | 4 | 7 |
| Withdrew: Withdrawal by subject | 1 | 3 | 3 |
| Withdrew: Withdrawal by parent/guardian | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 |
| Withdrew: Miscellaneous | 0 | 0 | 2 |
| Milestone | Dapagliflozin | Saxagliptin | Placebo |
|---|---|---|---|
| Started | 74 | 77 | 59 |
| Completed | 67 | 68 | 52 |
| Not completed | 7 | 9 | 7 |
| Withdrew: Withdrawal by subject | 2 | 1 | 0 |
| Withdrew: Withdrawal by parent/guardian | 2 | 3 | 2 |
| Withdrew: Lost to follow-up | 3 | 4 | 5 |
| Withdrew: Miscellaneous | 0 | 1 | 0 |
Data was analysed with an ANCOVA model with treatment, sex, age group and background antidiabetes medication as factors and Baseline HbA1c as covariate. Missing Week 26 data was handled based on multiple imputation washout (MI-WO) within each arm using the data from placebo participants with Week 26 data.
| Percentage HbA1c | Dapagliflozin | Placebo |
|---|---|---|
| Dapagliflozin Versus Placebo: Adjusted Mean Change From Baseline in HbA1c at Week 26 | -0.62 ± 0.218 | 0.41 ± 0.218 |
Data was analysed with an ANCOVA model with treatment, sex, age group and background antidiabetes medication as factors and Baseline HbA1c as covariate. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data.
| Percentage HbA1c | Saxagliptin | Placebo |
|---|---|---|
| Saxagliptin Versus Placebo: Adjusted Mean Change From Baseline in HbA1c at Week 26 | 0.06 ± 0.198 | 0.50 ± 0.202 |
Data was analysed with an ANCOVA model with treatment, sex, age group and background antidiabetes medication as factors and Baseline HbA1c as covariate. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data. Dapagliflozin participants were weighted as follows: participants who had HbA1c \< 7% at Week 12 and remained on low-dose were assigned a weight of 1; participants who had HbA1c \>= 7% at Week 12 and continued on the low-dose were assigned a weight of 0; participants who had HbA1c \>= 7% at Week 12 and received the high-dose were assigned a weight of 2; all participants who do not undergo second randomisation were assigned a weight of 1. Placebo participants were assigned a weight of 1.
| Percentage HbA1c | Dapagliflozin 5 mg/10 mg (Weighted) | Placebo (Weight = 1) |
|---|---|---|
| Dapagliflozin Low-dose/High-dose Versus Placebo (Weighted): Adjusted Mean Change From Baseline in HbA1c at Week 26 | -0.42 ± 0.214 | 0.43 ± 0.207 |
Data was analysed with an ANCOVA model with treatment, sex, age group and background antidiabetes medication as factors and Baseline HbA1c as covariate. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data. Saxagliptin participants were weighted as follows: participants who had HbA1c \< 7% at Week 12 and remained on low-dose were assigned a weight of 1; participants who had HbA1c \>= 7% at Week 12 and continued on the low-dose were assigned a weight of 0; participants who had HbA1c \>= 7% at Week 12 and received the high-dose were assigned a weight of 2; all participants who do not undergo second randomisation were assigned a weight of 1. Placebo participants were assigned a weight of 1.
| Percentage HbA1c | Saxagliptin 2.5 mg/5 mg (Weighted) | Placebo (Weight = 1) |
|---|---|---|
| Saxagliptin Low-dose/High-dose Versus Placebo (Weighted): Adjusted Mean Change From Baseline in HbA1c at Week 26 | -0.04 ± 0.190 | 0.47 ± 0.200 |
Data was analysed with an ANCOVA model with treatment, sex, age group and background antidiabetes medication as factors and Baseline HbA1c as covariate. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data. Dapagliflozin participants were weighted as follows: participants who had HbA1c \< 7% at Week 12 and remained on low-dose were assigned a weight of 1; participants who had HbA1c \>= 7% at Week 12 and continued on the low-dose were assigned a weight of 2; participants who had HbA1c \>= 7% at Week 12 and received the high-dose were assigned a weight of 0; all participants who do not undergo second randomisation were assigned a weight of 1. Placebo participants were assigned a weight of 1.
| Percentage HbA1c | Dapagliflozin 5 mg/10 mg (Weighted) | Placebo (Weight = 1) |
|---|---|---|
| Dapagliflozin Low-dose Versus Placebo (Weighted): Adjusted Mean Change From Baseline in HbA1c at Week 26 | -0.79 ± 0.202 | 0.40 ± 0.205 |
Data was analysed with an ANCOVA model with treatment, sex, age group and background antidiabetes medication as factors and Baseline HbA1c as covariate. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data. Saxagliptin participants were weighted as follows: participants who had HbA1c \< 7% at Week 12 and remained on low-dose were assigned a weight of 1; participants who had HbA1c \>= 7% at Week 12 and continued on the low-dose were assigned a weight of 2; participants who had HbA1c \>= 7% at Week 12 and received the high-dose were assigned a weight of 0; all participants who do not undergo second randomisation were assigned a weight of 1. Placebo participants were assigned a weight of 1.
| Percentage HbA1c | Saxagliptin 2.5 mg/5 mg (Weighted) | Placebo (Weight = 1) |
|---|---|---|
| Saxagliptin Low-dose Versus Placebo (Weighted): Adjusted Mean Change From Baseline in HbA1c at Week 26 | 0.07 ± 0.188 | 0.47 ± 0.194 |
Data was analysed with an ANCOVA model with treatment, sex, age group and background antidiabetes medication as factors and Baseline FPG as covariate. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data.
| mmol/L | Dapagliflozin | Placebo |
|---|---|---|
| Dapagliflozin Versus Placebo: Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 | -0.57 ± 0.374 | 0.51 ± 0.384 |
Data was analysed with an ANCOVA model with treatment, sex, age group and background antidiabetes medication as factors and Baseline FPG as covariate. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data.
| mmol/L | Saxagliptin | Placebo |
|---|---|---|
| Saxagliptin Versus Placebo: Adjusted Mean Change From Baseline in FPG at Week 26 | 0.08 ± 0.413 | 0.19 ± 0.428 |
Data was analysed with an ANCOVA model with treatment, sex, age group and background antidiabetes medication as factors and Baseline FPG as covariate. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data. Dapagliflozin participants were weighted as follows: participants who had HbA1c \< 7% at Week 12 and remained on low-dose were assigned a weight of 1; participants who had HbA1c \>= 7% at Week 12 and continued on the low-dose were assigned a weight of 0; participants who had HbA1c \>= 7% at Week 12 and received the high-dose were assigned a weight of 2; all participants who do not undergo second randomisation were assigned a weight of 1. Placebo participants were assigned a weight of 1.
| mmol/L | Dapagliflozin 5 mg/10 mg (Weighted) | Placebo (Weight = 1) |
|---|---|---|
| Dapagliflozin Low-dose/High-dose Versus Placebo (Weighted): Adjusted Mean Change From Baseline in FPG at Week 26 | -0.34 ± 0.365 | 0.70 ± 0.369 |
Data was analysed with an ANCOVA model with treatment, sex, age group and background antidiabetes medication as factors and Baseline FPG as covariate. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data. Saxagliptin participants were weighted as follows: participants who had HbA1c \< 7% at Week 12 and remained on low-dose were assigned a weight of 1; participants who had HbA1c \>= 7% at Week 12 and continued on the low-dose were assigned a weight of 0; participants who had HbA1c \>= 7% at Week 12 and received the high-dose were assigned a weight of 2; all participants who do not undergo second randomisation were assigned a weight of 1. Placebo participants were assigned a weight of 1.
| mmol/L | Saxagliptin 2.5 mg/5 mg (Weighted) | Placebo (Weight = 1) |
|---|---|---|
| Saxagliptin Low-dose/High-dose Versus Placebo (Weighted): Adjusted Mean Change From Baseline in FPG at Week 26 | 0.18 ± 0.331 | 0.73 ± 0.359 |
Data was analysed with an ANCOVA model with treatment, sex, age group and background antidiabetes medication as factors and Baseline FPG as covariate. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data. Dapagliflozin participants were weighted as follows: participants who had HbA1c \< 7% at Week 12 and remained on low-dose were assigned a weight of 1; participants who had HbA1c \>= 7% at Week 12 and continued on the low-dose were assigned a weight of 2; participants who had HbA1c \>= 7% at Week 12 and received the high-dose were assigned a weight of 0; all participants who do not undergo second randomisation were assigned a weight of 1. Placebo participants were assigned a weight of 1.
| mmol/L | Dapagliflozin 5 mg/10 mg (Weighted) | Placebo (Weight = 1) |
|---|---|---|
| Dapagliflozin Low-dose Versus Placebo (Weighted): Adjusted Mean Change From Baseline in FPG at Week 26 | -0.56 ± 0.347 | 0.56 ± 0.363 |
Data was analysed with an ANCOVA model with treatment, sex, age group and background antidiabetes medication as factors and Baseline FPG as covariate. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data. Saxagliptin participants were weighted as follows: participants who had HbA1c \< 7% at Week 12 and remained on low-dose were assigned a weight of 1; participants who had HbA1c \>= 7% at Week 12 and continued on the low-dose were assigned a weight of 2; participants who had HbA1c \>= 7% at Week 12 and received the high-dose were assigned a weight of 0; all participants who do not undergo second randomisation were assigned a weight of 1. Placebo participants were assigned a weight of 1.
| mmol/L | Saxagliptin 2.5 mg/5 mg (Weighted) | Placebo (Weight = 1) |
|---|---|---|
| Saxagliptin Low-dose Versus Placebo (Weighted): Adjusted Mean Change From Baseline in FPG at Week 26 | 0.63 ± 0.424 | 0.34 ± 0.446 |
A logistic regression model adjusting for sex, age group, background antidiabetes medication and Baseline HbA1c was used. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data.
| Percentage of participants | Dapagliflozin | Saxagliptin | Placebo |
|---|---|---|---|
| Percentage of Participants With Baseline HbA1c ≥ 7% Who Achieved HbA1c < 7% at Week 26 | 26.6 | 21.3 | 10.0 |
A weighted logistic regression model adjusting for sex, age group, background antidiabetes medication and Baseline HbA1c was used. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data. Participants were weighted as follows: participants who had HbA1c \< 7% at Week 12 and remained on low-dose were assigned a weight of 1; participants who had HbA1c \>= 7% at Week 12 and continued on the low-dose were assigned a weight of 0; participants who had HbA1c \>= 7% at Week 12 and received the high-dose were assigned a weight of 2; all participants who do not undergo second randomisation were assigned a weight of 1. Placebo participants were assigned a weight of 1.
| Percentage of participants | Dapagliflozin 5 mg/10 mg (Weighted) | Saxagliptin 2.5 mg/5 mg (Weighted) | Placebo (Weight = 1) |
|---|---|---|---|
| Low-dose/High-dose Versus Placebo (Weighted): Percentage of Participants With Baseline HbA1c ≥ 7% Who Achieved HbA1c < 7% at Week 26 | 27.3 | 24.4 | 10.0 |
A weighted logistic regression model adjusting for sex, age group, background antidiabetes medication and Baseline HbA1c was used. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data. Participants were weighted as follows: participants who had HbA1c \< 7% at Week 12 and remained on low-dose were assigned a weight of 1; participants who had HbA1c \>= 7% at Week 12 and continued on the low-dose were assigned a weight of 2; participants who had HbA1c \>= 7% at Week 12 and received the high-dose were assigned a weight of 0; all participants who do not undergo second randomisation were assigned a weight of 1. Placebo participants were assigned a weight of 1.
| Percentage of participants | Dapagliflozin 5 mg/10 mg (Weighted) | Saxagliptin 2.5 mg/5 mg (Weighted) | Placebo (Weight = 1) |
|---|---|---|---|
| Low-dose Versus Placebo (Weighted): Percentage of Participants With Baseline HbA1c ≥ 7% Who Achieved HbA1c < 7% at Week 26 | 35.6 | 28.9 | 10.0 |
Data was analysed with an ANCOVA model with treatment, sex, age group and background antidiabetes medication as factors and Baseline HbA1c as covariate. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data.
| Percentage HbA1c | Dapagliflozin 10 mg | Dapagliflozin 5 mg | Saxagliptin 5 mg | Saxagliptin 2.5 mg |
|---|---|---|---|---|
| Low-dose Versus Uptitration to the High Dose: Adjusted Mean Change From Baseline in HbA1c at Week 26 | -0.74 ± 0.368 | -0.71 ± 0.384 | -0.16 ± 0.361 | 0.07 ± 0.372 |
Data was analysed with an ANCOVA model with treatment, sex, age group and background antidiabetes medication as factors and Baseline FPG as covariate. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data.
| mmol/L | Dapagliflozin 10 mg | Dapagliflozin 5 mg | Saxagliptin 5 mg | Saxagliptin 2.5 mg |
|---|---|---|---|---|
| Low-dose Versus Uptitration to the High Dose: Adjusted Mean Change From Baseline in FPG at Week 26 | -1.62 ± 0.689 | -0.98 ± 0.683 | -2.38 ± 0.734 | -0.56 ± 0.763 |
A Fisher's exact test was used and unadjusted difference in percentage of participants and Clopper-Pearson CIs presented using imputed data. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data.
| Percentage of participants | Dapagliflozin 10 mg | Dapagliflozin 5 mg |
|---|---|---|
| Dapagliflozin Low-dose Versus Uptitration to the High Dose: Percentage of Participants With Baseline HbA1c ≥ 7% Who Achieved HbA1c < 7% at Week 26 | 5.3 | 25.0 |
A Fisher's exact test was used and unadjusted difference in percentage of participants and Clopper-Pearson CIs presented using imputed data. Missing Week 26 data was handled based on MI-WO within each arm using the data from placebo participants with Week 26 data.
| Percentage of participants | Saxagliptin 5 mg | Saxagliptin 2.5 mg |
|---|---|---|
| Saxagliptin Low-dose Versus Uptitration to the High Dose: Percentage of Participants With Baseline HbA1c ≥ 7% Who Achieved HbA1c < 7% at Week 26 | 8.7 | 15.0 |
Collected over All-cause mortality: Up to Week 104 Serious and other AEs: Up to 52 Weeks + 30 days (Week 56). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Weeks 1 to 14: Dapagliflozin 5 mg | 0/81 (0%) | 1/81 (1.2%) | 35/81 (43.2%) |
| Weeks 14 to 26: Dapagliflozin 5 mg | 0/55 (0%) | 0/55 (0%) | 14/55 (25.5%) |
| Weeks 14 to 26: Dapagliflozin 10 mg | 0/21 (0%) | 0/21 (0%) | 4/21 (19%) |
| Weeks 26 to 56: Dapagliflozin 5 mg | 0/55 (0%) | 5/55 (9.1%) | 26/55 (47.3%) |
| Weeks 26 to 56: Dapagliflozin 10 mg | 0/21 (0%) | 1/21 (4.8%) | 8/21 (38.1%) |
| Weeks 32 or 40 to 56: Dapagliflozin 10 mg + Metformin Withdrawal | 0/7 (0%) | 0/7 (0%) | 2/7 (28.6%) |
| Weeks 1 to 14: Saxagliptin 2.5 mg | 0/88 (0%) | 2/88 (2.3%) | 37/88 (42%) |
| Weeks 14 to 26: Saxagliptin 2.5 mg | 0/61 (0%) | 1/61 (1.6%) | 18/61 (29.5%) |
| Weeks 14 to 26: Saxagliptin 5 mg | 0/26 (0%) | 0/26 (0%) | 10/26 (38.5%) |
| Weeks 26 to 56: Saxagliptin 2.5 mg | 0/61 (0%) | 3/61 (4.9%) | 23/61 (37.7%) |
| Weeks 26 to 56: Saxagliptin 5 mg | 0/26 (0%) | 1/26 (3.8%) | 12/26 (46.2%) |
| Weeks 32 or 40 to 56: Saxagliptin 5 mg + Metformin Withdrawal | 0/13 (0%) | 0/13 (0%) | 3/13 (23.1%) |
| Weeks 1 to 14: Placebo | 0/76 (0%) | 1/76 (1.3%) | 39/76 (51.3%) |
| Weeks 14 to 26: Placebo | 0/70 (0%) | 1/70 (1.4%) | 24/70 (34.3%) |
| Weeks 26 to 32 or 40: Placebo | 0/70 (0%) | 3/70 (4.3%) | 29/70 (41.4%) |
| Weeks 32 or 40 to 56: Placebo | 0/53 (0%) | 0/53 (0%) | 2/53 (3.8%) |
| Weeks 32 or 40 to 56: Placebo to Dapagliflozin 10 mg + Metformin Withdrawal | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| Weeks 32 or 40 to 56: Placebo to Saxagliptin 5 mg + Metformin Withdrawal | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| Week 56 to 104: Non-treatment Follow-up Period | 0/210 (0%) | 0/210 (0%) | 0/210 (0%) |
| Event | Weeks 1 to 14: Dapagliflozin 5 mg | Weeks 14 to 26: Dapagliflozin 5 mg | Weeks 14 to 26: Dapagliflozin 10 mg | Weeks 26 to 56: Dapagliflozin 5 mg | Weeks 26 to 56: Dapagliflozin 10 mg | Weeks 32 or 40 to 56: Dapagliflozin 10 mg + Metformin Withdrawal | Weeks 1 to 14: Saxagliptin 2.5 mg | Weeks 14 to 26: Saxagliptin 2.5 mg | Weeks 14 to 26: Saxagliptin 5 mg | Weeks 26 to 56: Saxagliptin 2.5 mg | Weeks 26 to 56: Saxagliptin 5 mg | Weeks 32 or 40 to 56: Saxagliptin 5 mg + Metformin Withdrawal | Weeks 1 to 14: Placebo | Weeks 14 to 26: Placebo | Weeks 26 to 32 or 40: Placebo | Weeks 32 or 40 to 56: Placebo | Weeks 32 or 40 to 56: Placebo to Dapagliflozin 10 mg + Metformin Withdrawal | Weeks 32 or 40 to 56: Placebo to Saxagliptin 5 mg + Metformin Withdrawal | Week 56 to 104: Non-treatment Follow-up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HaematuriaRenal and urinary disorders | 0/81 | 0/55 | 0/21 | 0/55 | 1/21 | 0/7 | 0/88 | 0/61 | 0/26 | 0/61 | 0/26 | 0/13 | 0/76 | 0/70 | 0/70 | 0/53 | 0/3 | 0/3 | 0/210 |
| GastritisGastrointestinal disorders | 0/81 | 0/55 | 0/21 | 0/55 | 0/21 | 0/7 | 0/88 | 0/61 | 0/26 | 0/61 | 1/26 | 0/13 | 0/76 | 0/70 | 0/70 | 0/53 | 0/3 | 0/3 | 0/210 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/81 | 0/55 | 0/21 | 0/55 | 0/21 | 0/7 | 0/88 | 0/61 | 0/26 | 2/61 | 0/26 | 0/13 | 1/76 | 0/70 | 1/70 | 0/53 | 0/3 | 0/3 | 0/210 |
| Splenic ruptureInjury, poisoning and procedural complications | 0/81 | 0/55 | 0/21 | 1/55 | 0/21 | 0/7 | 0/88 | 0/61 | 0/26 | 0/61 | 0/26 | 0/13 | 0/76 | 0/70 | 0/70 | 0/53 | 0/3 | 0/3 | 0/210 |
| Glycosylated haemoglobin increasedInvestigations | 0/81 | 0/55 | 0/21 | 1/55 | 0/21 | 0/7 | 0/88 | 0/61 | 0/26 | 0/61 | 0/26 | 0/13 | 0/76 | 0/70 | 0/70 | 0/53 | 0/3 | 0/3 | 0/210 |
| Euglycaemic diabetic ketoacidosisMetabolism and nutrition disorders | 0/81 | 0/55 | 0/21 | 1/55 | 0/21 | 0/7 | 0/88 | 0/61 | 0/26 | 0/61 | 0/26 | 0/13 | 0/76 | 0/70 | 0/70 | 0/53 | 0/3 | 0/3 | 0/210 |
| LymphadenitisBlood and lymphatic system disorders | 0/81 | 0/55 | 0/21 | 1/55 | 0/21 | 0/7 | 0/88 | 0/61 | 0/26 | 0/61 | 0/26 | 0/13 | 0/76 | 0/70 | 0/70 | 0/53 | 0/3 | 0/3 | 0/210 |
| GastroenteritisInfections and infestations | 0/81 | 0/55 | 0/21 | 1/55 | 0/21 | 0/7 | 0/88 | 0/61 | 0/26 | 0/61 | 0/26 | 0/13 | 0/76 | 0/70 | 0/70 | 0/53 | 0/3 | 0/3 | 0/210 |
| Urinary tract infectionInfections and infestations | 0/81 | 0/55 | 0/21 | 1/55 | 0/21 | 0/7 | 0/88 | 0/61 | 0/26 | 0/61 | 0/26 | 0/13 | 0/76 | 0/70 | 0/70 | 0/53 | 0/3 | 0/3 | 0/210 |
| Accidental overdoseInjury, poisoning and procedural complications | 0/81 | 0/55 | 0/21 | 1/55 | 0/21 | 0/7 | 0/88 | 0/61 | 0/26 | 0/61 | 0/26 | 0/13 | 0/76 | 0/70 | 0/70 | 0/53 | 0/3 | 0/3 | 0/210 |
| Event | Weeks 1 to 14: Dapagliflozin 5 mg | Weeks 14 to 26: Dapagliflozin 5 mg | Weeks 14 to 26: Dapagliflozin 10 mg | Weeks 26 to 56: Dapagliflozin 5 mg | Weeks 26 to 56: Dapagliflozin 10 mg | Weeks 32 or 40 to 56: Dapagliflozin 10 mg + Metformin Withdrawal | Weeks 1 to 14: Saxagliptin 2.5 mg | Weeks 14 to 26: Saxagliptin 2.5 mg | Weeks 14 to 26: Saxagliptin 5 mg | Weeks 26 to 56: Saxagliptin 2.5 mg | Weeks 26 to 56: Saxagliptin 5 mg | Weeks 32 or 40 to 56: Saxagliptin 5 mg + Metformin Withdrawal | Weeks 1 to 14: Placebo | Weeks 14 to 26: Placebo | Weeks 26 to 32 or 40: Placebo | Weeks 32 or 40 to 56: Placebo | Weeks 32 or 40 to 56: Placebo to Dapagliflozin 10 mg + Metformin Withdrawal | Weeks 32 or 40 to 56: Placebo to Saxagliptin 5 mg + Metformin Withdrawal | Week 56 to 104: Non-treatment Follow-up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vitamin d deficiencyMetabolism and nutrition disorders | 2/81 | 1/55 | 0/21 | 2/55 | 0/21 | 0/7 | 4/88 | 1/61 | 0/26 | 0/61 | 1/26 | 0/13 | 5/76 | 1/70 | 2/70 | 0/53 | 0/3 | 1/3 | 0/210 |
| Ligament sprainInjury, poisoning and procedural complications | 0/81 | 0/55 | 0/21 | 0/55 | 0/21 | 0/7 | 1/88 | 0/61 | 1/26 | 0/61 | 0/26 | 0/13 | 0/76 | 1/70 | 0/70 | 0/53 | 1/3 | 0/3 | 0/210 |
| NasopharyngitisInfections and infestations | 1/81 | 2/55 | 0/21 | 1/55 | 1/21 | 0/7 | 2/88 | 1/61 | 0/26 | 0/61 | 0/26 | 2/13 | 2/76 | 0/70 | 3/70 | 1/53 | 0/3 | 0/3 | 0/210 |
| PharyngotonsillitisInfections and infestations | 1/81 | 0/55 | 0/21 | 1/55 | 1/21 | 1/7 | 0/88 | 0/61 | 0/26 | 0/61 | 0/26 | 0/13 | 1/76 | 0/70 | 1/70 | 0/53 | 0/3 | 0/3 | 0/210 |
| TonsillitisInfections and infestations | 0/81 | 0/55 | 0/21 | 0/55 | 0/21 | 1/7 | 1/88 | 0/61 | 0/26 | 0/61 | 0/26 | 0/13 | 0/76 | 0/70 | 0/70 | 0/53 | 0/3 | 0/3 | 0/210 |
| HeadacheNervous system disorders | 6/81 | 5/55 | 0/21 | 2/55 | 2/21 | 0/7 | 2/88 | 1/61 | 0/26 | 1/61 | 0/26 | 0/13 | 1/76 | 2/70 | 1/70 | 0/53 | 0/3 | 0/3 | 0/210 |
| DysmenorrhoeaReproductive system and breast disorders | 0/81 | 1/55 | 0/21 | 0/55 | 2/21 | 0/7 | 1/88 | 1/61 | 0/26 | 0/61 | 0/26 | 0/13 | 2/76 | 0/70 | 1/70 | 0/53 | 0/3 | 0/3 | 0/210 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/81 | 0/55 | 0/21 | 0/55 | 0/21 | 0/7 | 0/88 | 0/61 | 0/26 | 0/61 | 0/26 | 1/13 | 0/76 | 0/70 | 1/70 | 0/53 | 0/3 | 0/3 | 0/210 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/81 | 0/55 | 0/21 | 0/55 | 0/21 | 0/7 | 0/88 | 0/61 | 0/26 | 0/61 | 0/26 | 1/13 | 1/76 | 0/70 | 0/70 | 0/53 | 0/3 | 0/3 | 0/210 |
| ToothacheGastrointestinal disorders | 0/81 | 0/55 | 0/21 | 1/55 | 1/21 | 0/7 | 0/88 | 0/61 | 2/26 | 1/61 | 1/26 | 0/13 | 0/76 | 0/70 | 0/70 | 0/53 | 0/3 | 0/3 | 0/210 |
Randomised Participants Data Set: consisted of all randomised participants who receive at least one dose of study medication during the treatment period.
| Age, Continuous(years) | Dapagliflozin | Saxagliptin | Placebo | Total |
|---|---|---|---|---|
| Mean | 14.4 ± 2.00 | 14.5 ± 1.75 | 14.7 ± 1.64 | 14.5 ± 1.80 |
| Sex: Female, Male(Participants) | Dapagliflozin | Saxagliptin | Placebo | Total |
|---|---|---|---|---|
| Female | 49 | 53 | 44 | 146 |
| Male | 32 | 35 | 32 | 99 |
| Ethnicity (NIH/OMB)(Participants) | Dapagliflozin | Saxagliptin | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 45 | 43 | 34 | 122 |
| Not Hispanic or Latino | 36 | 45 | 42 | 123 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Dapagliflozin | Saxagliptin | Placebo | Total |
|---|---|---|---|---|
| White | 42 | 50 | 32 | 124 |
| Black or African American | 7 | 4 | 3 | 14 |
| Asian | 18 | 23 | 24 | 65 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 3 | 3 |
| American Indian or Alaska Native | 11 | 7 | 12 | 30 |
| Other | 3 | 4 | 2 | 9 |
| Mean Baseline HbA1c(Percentage HbA1c) | Dapagliflozin | Saxagliptin | Placebo | Total |
|---|---|---|---|---|
| Mean | 8.22 ± 1.459 | 8.02 ± 1.431 | 7.96 ± 1.629 | 8.07 ± 1.502 |
Showing the first 100 of 122 sites across 23 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Oct 2017 to primary completion in Feb 2023, 63 months.
Results were first posted in Apr 2024, 1 year 2 months after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 63 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dapagliflozin · Saxagliptin